Early and effective treatment of KCNQ2 encephalopathy

Epilepsia

Volumn 56, Issue 5, 2015, Pages 685-691

  Pisano, Tiziana ^a   Numis, Adam L ^b   Heavin, Sinéad B ^c   Weckhuysen, Sarah ^d,e   Angriman, Marco ^f   Suls, Arvid ^d,e   Podesta, Barbara ^g   Thibert, Ronald L ^h   Shapiro, Kevin A ^b   Guerrini, Renzo ^a,i   Scheffer, Ingrid E ^c   Marini, Carla ^a   Cilio, Maria Roberta ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f CENTRAL HOSPITAL OF BOLZANO   (Italy)

^g SC Pediatria   (Italy)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiepileptic drug treatment; Epilepsy; KCNQ2 encephalopathy

Indexed keywords

ANTICONVULSIVE AGENT; BIOTIN; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; FOLINIC ACID; MIDAZOLAM; OXCARBAZEPINE; PHENYTOIN; POTASSIUM CHANNEL KCNQ2; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; TOPIRAMATE; VALPROIC ACID;

ARTICLE; BENIGN CHILDHOOD EPILEPSY; BRAIN DISEASE; CHILD; CLINICAL ARTICLE; CLONIC SEIZURE; COGNITIVE DEVELOPMENT; DRUG DOSE REDUCTION; EARLY INTERVENTION; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENE MUTATION; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MONOTHERAPY; MOTOR DEVELOPMENT; NEUROIMAGING; NEWBORN PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; EPILEPSY; GENETICS; INFANT; MOVEMENT DISORDERS; MULTICENTER STUDY; MUTATION; PHARMACOGENETICS; PRESCHOOL CHILD;

ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; HUMANS; INFANT; KCNQ2 POTASSIUM CHANNEL; MALE; MOVEMENT DISORDERS; MUTATION; NEUROIMAGING; PHARMACOGENETICS; RETROSPECTIVE STUDIES;

EID: 84929517245     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12984     Document Type: Article

References (26)

1. Cross JK, Guerrini R,. The epileptic encephalopathies. Handb Clin Neurol 2013; 111: 619-626.
2. Esmaeeli Nieh S, Sherr EH,. Epileptic encephalopathies: new genes and new pathways. Neurotherapeutics 2014; 11: 796-806.
3. Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen AS, et al., De novo mutations in epileptic encephalopathies. Nature 2013; 501: 217-221.
4. EuroEPINOMICS-RES Consortium, Epi4K Consortium, Epilepsy Phenome/Genome Project. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 2014; 95: 360-370.
5. Leppert M, Anderson VE, Quattlebaum T, et al., Benign familial neonatal convulsions linked to genetic markers on chromosome 20. Nature 1989; 337: 647-648.
6. Singh NA, Charlier C, Stauffer D., et al., A novel potassium channel gene, KCNQ2, is mutated an inherited epilepsy of newborns. Nat Genet 1998; 18: 25-29.
7. Biervert C, Steinlein OK,. Structural and mutational analysis of KCNQ2, the major gene locus for benign familial neonatal convulsions. Hum Genet 1999; 104: 234-240.
8. Weckhuysen S, Mandelstam S, Suls A, et al., KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 2012; 71: 15-25.
9. Weckhuysen S, Ivanovic V, Hendrickx R, et al., Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 2013; 81: 1697-1703.
10. Milh M, Boutry-Kryza N, Sutera-Sardo J, et al., Similar early characteristics but variable neurological outcome of patients with a de novo mutation of KCNQ2. Orphanet J Rare Dis 2013; 8: 80.
11. Numis AL, Angriman M, Sullivan JE, et al., KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. Neurology 2014; 82: 368-370.
12. Carvill GL, Heavin SB, Yendle SC, et al., Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 2013; 45: 825-830.
13. Murray G, Jones P, Kuh D, et al., Infant developmental milestones and subsequent cognitive function. Ann Neurol 2007; 62: 128-136.
14. Volpe JJ,. Neonatal seizures. In, Volpe JJ, (Ed) Neonatal neurology. 5th Ed. Philadelphia, PA: WB Saunders, 2008: 203-244.
15. Kato M, Yamagata T, Kubota M, et al., Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia 2013; 54: 1282-1287.
16. Serino D, Specchio N, Pontrelli G, et al., Video/EEG findings in a KCNQ2 epileptic encephalopathy: a case report and revision of literature data. Epileptic Disord 2013; 15: 158-165.
17. Miceli F, Soldovieri MV, Ambrosino P, et al., Genotype-phenotype correlations in neonatal epilepsies caused by mutations in the voltage sensor of K(v)7.2 potassium channel subunits. Proc Natl Acad Sci U S A 2013; 110: 4386-4391.
18. Ambrõsio AF, Silva AP, Malva JO, et al., Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 2010; 38: 1349-1359.
19. Arya R, Glauser TA,. CNS pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. Drugs 2013; 27: 273-286.
20. Pan Z, Kao T, Horvath Z, et al., A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J Neurosci 2006; 26: 2599-2613.
21. Nguyen HM, Miyazaki H, Hoshi N, et al., Modulation of voltage-gated K+ channels by the sodium channel ß1 subunit. Proc Natl Acad Sci U S A 2012; 109: 18577-18582.
22. Shank RP, Gardocki JF, Streeter AJ, et al., An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41: 3-9.
23. Lyseng-Williamson KA,. Levetiracetam: a review of its use in epilepsy. Drugs 2011; 71: 489-514.
24. Barrese V, Miceli F, Soldovieri MV, et al., Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clin Pharmacol 2010; 2: 225-236.
25. Gunthorpe MJ, Large CH, Sankar R,. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012; 53: 412-424.
26. Splinter MY,. Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults. J Cent Nerv Syst Dis 2013; 5: 31-41.